Trial reportClinical journal of the American Society of Nephrology : CJASN2012
Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial.
Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- The effect of perioperative erythropoietin-stimulating agents and intravenous iron on patient outcomes following solid organ transplantation: A systematic review.Transfusion medicine (Oxford, England) · 2026Pooled it
- A systematic review and meta-analysis of factors contributing to post-kidney transplant anemia and the effect of erythropoietin-stimulating agents.Systematic reviews · 2024Pooled it
- Harms of off-label erythropoiesis-stimulating agents for critically ill people.The Cochrane database of systematic reviews · 2017Pooled it
- Erythropoiesis stimulating agents and reno-protection: a meta-analysis.BMC nephrology · 2017Pooled it
- Effect of Perioperative Dexmedetomidine on Delayed Graft Function Following a Donation-After-Cardiac-Death Kidney Transplant: A Randomized Clinical Trial.JAMA network open · 2022Trial
- Effect of N-acetylcysteine pretreatment of deceased organ donors on renal allograft function: a randomized controlled trial.Transplantation · 2015Trial
- rhErythropoietin-b as a tissue protective agent in kidney transplantation: a pilot randomized controlled trial.BMC research notes · 2015Trial
- Immune Infiltration-Related Genes as Potential Biomarkers and Predicted Targets for Renal Allograft Delayed Graft Function and Survival Outcome: An Integrated Machine Learning Approach and Drugs Analysis.Mediators of inflammation · 2026Article
- Targeting the innate repair receptor axisFrontiers in immunology · 2022Article
- Treatment of anemia in difficult-to-manage patients with chronic kidney disease.Kidney international supplements · 2021Article
- Erythropoietin Receptor/β Common Receptor: A Shining Light on Acute Kidney Injury Induced by Ischemia-Reperfusion.Frontiers in immunology · 2021Review
- Kidney-intrinsic factors determine the severity of ischemia/reperfusion injury in a mouse model of delayed graft function.Kidney international · 2020Article
- Prognostic value for long-term graft survival of estimated glomerular filtration rate and proteinuria quantified at 3 months after kidney transplantation.Clinical kidney journal · 2020Article
- Posttransplantation anemia in kidney transplant recipients: A retrospective cohort study.Medicine · 2017Observational
- Delayed graft function and its management in children.Pediatric nephrology (Berlin, Germany) · 2017Review
- Bridging Translation by Improving Preclinical Study Design in AKI.Journal of the American Society of Nephrology : JASN · 2015Review
- Strategies to optimize kidney recovery and preservation in transplantation: specific aspects in pediatric transplantation.Pediatric nephrology (Berlin, Germany) · 2015Review
- Cyclic Helix B Peptide in Preservation Solution and Autologous Blood Perfusate Ameliorates Ischemia-Reperfusion Injury in Isolated Porcine Kidneys.Transplantation direct · 2015Article
- Erythropoietin and organ protection: lessons from negative clinical trials.Critical care (London, England) · 2014Article
- Renoprotective capacities of non-erythropoietic EPO derivative, ARA290, following renal ischemia/reperfusion injury.Journal of translational medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesDelayed graft function (DGF) is associated with adverse long-term outcomes after deceased-donor kidney (DDK) transplantation. Ischemia-reperfusion injury plays a crucial role in the development of DGF. On the basis of promising animal data, this study evaluated any potential benefits of erythropoietin-alfa (EPO-α) given intra-arterially at the time of reperfusion of renal allograft on the degree of allograft function, as well as tubular cell injury measured by urinary biomarkers in the early post-transplant period. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A prospective, randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the influence of EPO-α administered intraoperatively on the outcomes of DDK transplantations performed at the study center between March 2007 and July 2009.
resultsSeventy-two patients were randomly assigned to EPO-α (n=36) or placebo (n=36). The incidences of DGF, slow graft function, and immediate graft function did not significantly differ between the treatment and control groups (41.7% versus 47.2%, 25.0% versus 36.1%, and 33.3% versus 16.7%, respectively; P=0.24). The groups had similar levels of urinary biomarkers, including neutrophil gelatinase-associated lipocalin and IL-18 at multiple times points soon after transplantation; urinary output during the first 3 postoperative days; 1-month renal function; and BP readings, hemoglobin, and adverse effects during the first month.
conclusionsThis study did not show any clinically demonstrable beneficial effects of high-dose EPO-α given intra-arterially during the early reperfusion phase in DDK transplant recipients in terms of reducing the incidence of DGF or improving short-term allograft function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.